[¹⁸F]FluorThanatrace PET imaging as a biomarker of response to PARP inhibitors in breast cancer.

ABSTRACT:

Background

Poly (ADP-ribose) polymerase inhibitors (PARPi) are approved for Breast Cancer gene (BRCA)-mutant HER2- breast cancer, and there is clinical interest in expanding indications to include homologous recombination deficient (HRD) breast cancers. Yet, response in these populations remains variable, suggesting clinical utility in developing a better biomarker to select patients for PARPi and predict response. Here, we evaluate a radiolabeled PARPi, [¹⁸F]FluorThanatrace ([¹⁸F]FTT), as a functional biomarker of PARPi response in breast cancer.

Methods

A single-arm prospective observational trial was conducted at the University of Pennsylvania. [¹⁸F]FTT-PET uptake was measured in 24 women with untreated primary breast cancer and correlated

SUBMITTER: Gitto SB 

PROVIDER: S-EPMC11937411 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature